Cargando…
Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia
BACKGROUND: Although tolvaptan treatment improves hyponatremia, only few studies have investigated whether tolvaptan actually benefits the survival of cirrhotic patients. This study evaluated the impact of tolvaptan on six-month survival of decompensated cirrhotic patients with and without hyponatre...
Autores principales: | Wang, Shuzhen, Zhang, Xin, Han, Tao, Xie, Wen, Li, Yonggang, Ma, Hong, Liebe, Roman, Weng, Honglei, Ding, Hui-Guo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123923/ https://www.ncbi.nlm.nih.gov/pubmed/30180806 http://dx.doi.org/10.1186/s12876-018-0857-0 |
Ejemplares similares
-
Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites
por: Hosui, Atsushi, et al.
Publicado: (2021) -
Impact of continued administration of tolvaptan on cirrhotic patients with ascites
por: Kogiso, Tomomi, et al.
Publicado: (2018) -
Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan
por: Adachi, Takuya, et al.
Publicado: (2021) -
The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan
por: Kogiso, Tomomi, et al.
Publicado: (2017) -
Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites
por: Hirooka, Masashi, et al.
Publicado: (2022)